Clinical Trials Browser

Interventional × lazertinib × 1 year × Clear all

NCT04077463 2026-03-17

Chrysalis-2

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06120140 2026-03-13

COCOON

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06106802 2026-02-23

Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment

Phase 2 Recruiting

Non-Small Cell Lung Cancer Metastatic

NCT05498428 2026-02-13

PALOMA-2

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06268210 2026-02-09

NeoLazer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04988295 2026-02-05

MARIPOSA-2

Phase 3 Active not recruiting

776 enrolled 13 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04487080 2026-02-04

MARIPOSA

Phase 3 Active not recruiting

1,074 enrolled 13 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT05786430 2026-01-27

LUCAS

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05601973 2026-01-21

AMAZE-lung

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02609776 2026-01-16

CHRYSALIS

Phase 1 Active not recruiting

751 enrolled 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT06667076 2026-01-16

COPERNICUS

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04965090 2025-12-18

A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT05299125 2025-10-01

AMIGO-1

Phase 2 Active not recruiting

Metastatic Non-small Cell Lung Cancers

NCT05541822 2025-05-22

To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

Phase 2 Recruiting

Other solid neoplasm

Advanced Solid Tumors